1 Dorta G, et al. Recommandations consensuelles révisées. Suivi postpolypectomie colique et suivi des cancers colorectaux après opération curative. Swiss Medical Forum. 2016;16:164–7.
2 Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.
3 Hassan E, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy. 2020;52:1–14.
4 Rutter MD, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut. 2020;69:201–23.
5 Gupta S, et al. Recommendations for Follow-Up after Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020;158:1131–53.
6 He X, et al. Long-Term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serraed Polyps. Gastroenterology. 2020;158:852–61.
7 Lee JK, et al. Long-Term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology. 2020;158:884–94.
8 Lieberman D et al. Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance. Gastroenterology. 2020;158:862–74.
9 Wieszczy P, et al. Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies. Gastroenterology. 2020;158:875–83.
10 Click B, et al. Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence. JAMA. 2018;319:2021–31.
11 Dubé C, et al. Risk of Advanced Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality in People With Low-Risk Adenomas at Baseline Colonoscopy: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017;112:1790–801.
12 Cross AJ, et al. Colorectal cancer risk following polypectomy in a multicentre, retrospective, cohort study: an evaluation of the 2020 UK post-polypectomy surveillance guidelines. Gut. 2021;0:1–14.
13 Duvvuri A, et al. Detection of Low-Risk or High-Risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology. 2021;160:1986–96.
14 Holme O, et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2015;64:929–36.
15 Erichsen R, et al. Increased risk of colorectal cancer development among patients with serrated polyps. Gastroenterology. 2016;150:895–902.
16 Lugli A, et. al. Tumor budding in solid cancers. Nature Reviews Clinical Oncology. 2020;18:101–15.
17 Jover R, et al. Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy. 2016;48:571–8.
18 Djinbachian R, et al. Adherence to post-polypectomy surveillance guidelines: a systematic review and meta-analysis. Endoscopy. 2019;51:673–83.
19 Zgraggen A, et al. Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss screening study – outcomes, adherence, and costs. Z. Gastroenterol. 2022;1–18, in press.
20 Grothey A, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177–88.
21 Wille-Jorgensen P, et al. Effect of more or less frequent follow-up testing on overall and colorectal-specific mortality in patients with stage II or III colorectal cancer. The COLOFOL randomized clinical trial. JAMA. 2018:319:2095–103.
22 Verberne CJ, et al. Intensifiied follow-up in colorectal cancer using frequent carcino-embryonic (CEA) measurements and CEA-triggered imaging: results of the randomized «CEAwatch» trial. Eur J Surg Oncol. 2015;41:1188–96.
23 Snyder RA, et al. Association between intensity and postreatment surveillance testing and detection of recurrence in patients with colorectal cancer. JAMA. 2018;319:2104–15.
24 Primrose JN, et al. Effects of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer. The FACS randomized clinical trial. JAMA. 2014;311:263–270.
25 Lepage C, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: PRODIGE 13 a FFCD phase III trial. ESMO Virtual Congress 2020; Abstract 390O. Presented September 19,2020.
26 Bastiaenen VP, et al. Consensus and controversies regarding follow-up after treatment with curative intend of non-metastatic colorectal cancer: a synpopsis of guidelines used in countries represented in the European Scociety of Coloproctology. Colorectal Dis. 2019;21:392–416.
27 Van der Stok EP, et al. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. 2017;14:297–315.
28 Jeffery M, et al. Follow-up stategies for patients treated for non-metastastic colorectal cancer (review). Cochrane Database Syst Rev. 216; 11:CD002200.
29 Badadoer RR, et al. A short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.
30 Fernandez LM, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43–50.
31 Thompson H, et al. Survival and organ preservation according to clinical response after total neoadjuvant therapy in locall advanced rectal cancer patients: A secundary analysis from the organ preservation in rectal adenocarcinoms (OPRA) trial. ASCO Annual Meeting. 2021;39:Abstract 3509.
32 Fokas E, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18(:805–16.
33 Kawaguchi Y, et al. A new surveillance algorithm after resection of colorectal liver metastases based on changes in recurrence risk and RAS mutational status. J Natl Compr Netw. 2020;18:1500–8.